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1. Introduction
Translational research combines basic and clinical science to
promote knowledge in prevention, diagnosis, and therapy of
human disease. The final goal is the promotion of quality of
life and society well-being.[1] Likewise, a translational chemistry
approach would provide the initial foundation to understand
human diseases at the molecular level. Using chemical tools,[2]
chemists can connect molecular information and biological
function or dysfunction. This methodology has been used in
the areas of medicinal chemistry, chemical biology, and bio-
chemistry. Additionally, it is possible to link molecular informa-
tion and to establish physicochemical models to understand
complex systems, such as those observed in human diseases.
This last strategy is commonly used in physical organic chemis-
try research, and as Prof. George Whitesides recently defined,
“it is not really about physical chemistry, organic chemistry, or
even chemistry. It is a strategy for the design of programs in
experimental scientific research, which offers a general, and re-
markably versatile, method for tackling complex problems.”[3]
From the perspective of the aforementioned chemical disci-
plines and the idea to translate this knowledge into biomedical
research, we embarked recently on translational chemistry re-
search to shed light on the complicated immunological disor-
ders related to gluten. Herein, we review these diseases from a
clinical point of view to the up-to-now molecular and supra-
molecular understanding.
2. Gluten-Related Disorders: The Clinical Point
of View
Gluten-related disorders are complex immune-mediated dis-
eases that affect around 1–7% of the general population.[4]
They are named according to clinical symptoms and type of
immunological response, for example, wheat allergy, celiac dis-
ease (CD), gluten ataxia, dermatitis herpetiformis, and nonceli-
ac gluten sensitivity (NCGS) (Figure 1). It is assumed that there
must be a particular susceptibility in an individual that could
trigger these kinds of diseases, but parameters have not yet
been well clarified, except for CD,[5] for which HLA-DQ genes
are of invaluable importance in the diagnosis given that virtu-
ally all CD patients (>97%) carry the coding variants for HLA-
DQ2 and/or HLA-DQ8 molecules.[6] However, although carriage
of the HLA-DQ2/DQ8 haplotype is an essential factor in the
pathogenesis of CD, it has low predictive value.[5] This is illus-
trated by the fact that whereas 30–40% of the general popula-
tion carries this genotype, the prevalence of CD is about 1%
worldwide.[7] Genome-wide association studies (GWASs) have
shown that there are also non-HLA genes involved in the dis-
ease.[8] Up to now, diagnostic tools for diagnosis exist only for
CD and dermatitis herpetiformis. In the case of CD, these strat-
egies are genetic markers (HLA-DQ2/DQ8), specific serological
antibodies (anti-transglutaminase antibodies), histopathological
analysis of the duodenal–jejunal biopsy specimens, and the
clinical response to the implementation of a gluten-free diet
(GFD).[9]
CD is the most common food intolerance in western soci-
ety.[11] It is an autoimmune enteropathy that may present not
only with intestinal manifestations but also systemic ones,
such as anemia, loss of weight, short stature, osteoporosis, and
peripheral neuropathy.[12] Other specific conditions associated
with CD are, for example, Addison’s disease, non-Hodgkin lym-
phoma, neurological disorders, and type I diabetes mellitus.[13]
As CD cannot be cured pharmacologically,[14] the only effective
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treatment for gluten-related disorders is a life-long abolish-
ment of gluten from the diet.
A strict gluten-free diet (GFD) improves the clinical symp-
toms, diminishes the titers of the CD-specific antibodies, and fi-
nally heals the intestinal mucosa and restores health. In daily
life, adhering to a GFD appears to be difficult and has a huge
impact on the quality of life of the patient.[15] The two main
long-term complications of not following a GFD in CD are os-
teoporosis and malignancy. Also, prolonged gluten consump-
tion in nondiagnosed individuals may contribute to the refrac-
tory forms of CD, for which there is no response to a GFD and,
therefore, intestinal inflammation is maintained. There are two
forms of refractory CD: type I, which responds to immunomo-
dulators, and type II, for which there is no effective treatment,
and this type is associated with an increased incidence of T-
cell lymphoma.[16]
In these days, there is a broad field of research dedicated to
finding new alternatives that reduce the immunogenicity of
gluten in cereals to prevent people from triggering an immune
response.[17] The most-advanced studies are devoted to prolyl
endopeptidases degrading toxic gluten peptides (ALV003, AN-
PEP)[18] For AN-PEP[19] and larazotide acetate (AT-1001, human
zonulin inhibitor),[20] clinical trials have been conducted. How-
ever, they will not become an alternative to a gluten-free diet
but rather a supplement to it, which will enable patients to
ease nutritional restrictions. Another potentially promising ap-
proach is nutritional therapy. Various dietary components in-
cluding long-chain w-3 fatty acids, plant flavonoids, and caro-
tenoids have been demonstrated to modulate oxidative stress,
gene expression, and production of inflammatory mediators.
Therefore, their adoption could preserve intestinal barrier in-
tegrity and, hence, could play a protective role against toxicity
of gliadin peptides.[21] The other gluten-related disorders are
much less understood from a molecular perspective. Actually,
in the case of nonceliac gluten sensitivity the diagnosis can
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only be made by exclusion of gluten from the diet (refer to
more specialized Review articles[4,9]). Taking into account the in-
creased spectrum of gluten-related disorders and the estimat-
ed high and increasing prevalence of these diseases,[4, 14] it is
highly desirable to come to a full understanding of these path-
ologies from a molecular point of view to provide better diag-
nosis and appropriate treatment.
3. What is Gluten? A General Description
All aforementioned gluten-related disorders have a common
trigger, that is, the contact or consumption of gluten. The term
“gluten”, as described in the dictionary, is “the tough, viscid, ni-
trogenous substance remaining when the flour of wheat or
other grain is washed to remove the starch and it gives to
dough its tough elastic character”.[22] From a chemical point of
view, gluten is composed mainly of proteins with a high con-
tent of the amino acids glutamine and proline in their se-
quence, generally referred to as prolamins. In the seed, prola-
mins act as a storage source of nitrogen for germination.[23]
The major prolamin from wheat is gliadin, but homologous
proteins are found in barley (hordeins), rye (secalins), and oat
(avenins). The prolamin proteins of these cereals undergo in-
complete enzymatic degradation during in vivo digestion,
which produces peptides that result in toxicity in predisposed
individuals. In wheat gluten, there are two main types of pro-
teins: one is the alcohol-insoluble fraction, which is traditional-
ly called glutenins, and the alcohol-soluble fraction called is
gliadins.[24]
4. The Structure of Gliadin Proteins
The most-studied protein related to gluten-consumption dis-
eases is gliadin, the prolamin from wheat.[25] It is composed of
different isoforms that are classified as a (25–35 kDa), b (30–
35 kDa), g (35–40 kDa), and w (55–75 kDa) depending on their
electrophoretic mobility.[26] These proteins share a similar pri-
mary structure consisting of an N-terminal domain; a hydro-
phobic central domain that is rich in proline, glutamine, and
phenylalanine; and a nonrepeating region including cysteine
(Figure 2). The a- and b-gliadins have between 250 and 300
amino-acid residues with a very similar structure and sequence,
so they are usually grouped. Also, a/b- and g-gliadins contain
six and eight cysteine residues, respectively, that are located in
a conserved position. The w-gliadin possesses 350 amino acids
and is globally more polar than the rest of the isoforms. It
does not contain the amino acid cysteine in its composition,
and for that reason, it is not able to present a cross-linking
through disulfide bridges.[27] Similar to other gliadins, w-gliadin
is also characterized by high contents of proline and gluta-
mine, which are located in a repetitive and characteristic se-
quence PQQPFPQQ.[28] All gliadins possess few positively
charged amino acids. Although this group of proteins has
been studied extensively, elucidation of their secondary and
tertiary structures is scarce. Whereas under normal environ-
mental conditions crystallization of the proteins fails, in a mi-
crogravimetric environment it is possible to elucidate their
structure.[29] The main reason for the lack of structural informa-
tion is the low solubility of gliadin in water, its high molecular
weight, and its high proline content.[25c] These intrinsic charac-
teristics make it difficult to obtain structural information
Figure 1. Pathogenesis of gluten-related disorders. The percentages correspond to the prevalence of each disease in the general population (adapted from
Sapone et al.[10] and Fasano et al.[4]).
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through high-resolution techniques such as nuclear magnetic
resonance or X-ray diffraction. That is why structural informa-
tion for this protein has been obtained mainly from spectro-
scopic techniques.[30] Gliadin can be solubilized in water by
using mixtures of salts and alcohols. Using Raman spectrosco-
py, Blanch et al.[31] have shown that a-gliadins possess a high
a-structure content, and to a lesser extent, b sheet and poly-
proline II (PPII) structures at pH 3.5. In the case of w-gliadins, a
well-defined PPII structure has been determined with some b
turns at pH 2.6. Moreover, Tatham and Shewry have shown by
circular dichroism that an ethanol solution (70%, v/v) of a-, b-,
and g-gliadins presents with 36–37% a helix, 11–12% b sheet,
and 52–53% random structure and b turns. They also describe
that a-, b-, and g-gliadins are stabilized by hydrogen bonds
and disulfur bridges, whereas w-gliadins are stabilized by hy-
drophobic interactions.[32]
5. The Self-Assembly Properties of Gliadin:
A Supramolecular View
Previous studies have pointed out that gliadin can self-assem-
ble under different conditions in aqueous media. By desolva-
tion, gliadin generates spherical aggregates with diameters in
the range of 100 to 500 nm. This method consists of treating a
protein with a precipitant solvent and has been employed to
obtain nanoparticles of gliadin as a colloidal system for drug
delivery.[34] Additionally, gliadin self-organizes in aqueous
media to form metastable supramolecular structures. Kasarda
et al. have demonstrated that a-gliadin reversibly aggregates
into fibrils at pH 5.0 in acetic acid and low ionic strength, and
this process can be modulated by lowering the pH.[35] More-
over, Sato et al. have shown that a solution of gliadin in dis-
tilled water below 10 wt% with high ionic strength is com-
posed mainly of ellipsoid monomers that are 11.3 nm in length
and 2.5 nm in width, with small amounts of dimers and oligo-
mers. Above 15 wt%, gliadins form gel-like hydrated solids,
and at higher concentrations, larger aggregates are present.[36]
More recently, it has been reported that if a mixture of com-
mercial gliadins is dissolved and homogenized in water at
pH 3.0 under low ionic strength, a- and b-gliadins self-organize
(Figure 3). The self-assembly process is spontaneous, and nano-
spherical structures are stabilized in the transparent water so-
lution. If the pH is changed to 7.0, phase separation is ob-
served, whereas the a-gliadins remain in solution as nanoparti-
cle aggregates. Although no differences are detected in the
secondary structure at either pH value, differential exposition
of tyrosine and tryptophan is observed, which can be caused
by a tertiary structure change. To evaluate structural changes,
such as the exposure of hydrophobic sites, Nile Red (NR) fluo-
rescence can be employed. By using this technique, this fluoro-
phore increases the fluorescence of a-gliadin and the maxi-
mum emission is blueshifted at pH 3 (relative to that of pure
a-gliadin), but not at pH 7.0. This behavior is indicative of NR
binding to gliadin and suggests that hydrophobic sites are ac-
cessible at pH 3.0. These results further indicate that at pH 3.0
the system is self-organized as micellar nanostructures, where-
as at pH 7.0 the structures have a lower surface charge (from
+13 mV at pH 3.0 to +4 mV at pH 7.0) and colloidal nano- and
microparticles are detected.[37]
The formation of these nanostructures in the digestive
system may block the degradation sites of the digestive en-
Figure 2. Sequence alignment of representative sequences of a- (Q9FUW7),
a/b- (P08453), g-(Q9M4L6) and w-gliadins (P18573) by using ESPript 3.0.[33]
The conserved residues are in white with a red background. Residues in red
are similar within a group, and residues framed in blue are similar across
groups. Figure 3. Supramolecular organization of gliadin in aqueous medium report-
ed by Herrera et al.[37] Although both solutions are clear and transparent,
gliadin molecules are not randomly dispersed in water ; instead, they self-as-
semble to form micellar oligomers or nanoparticles depending on the pH
value.
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zymes. By simulation, the a-2 gliadin protein is anticipated to
be cleaved by pepsin in 48 positions and by chymotrypsin in
35 locations, but in reality, this does not happen. In that case,
the supramolecular behavior of gliadin under physiological
conditions at pH 3.0 and 7.0 offers an essential clue to the un-
derstanding of why pepsin or chymotrypsin in vivo does not
fully degrade this protein. Of course, once in the small intes-
tine the high amount of proline plays a crucial role in endo-
peptidase activity, but the high content of proline by itself
does not explain the proteolytic resistance observed.
6. The Interaction of a-Gliadin and Its Proteo-
lytic-Resistant Peptides with the Intestinal
Mucosa
Among gliadins, the a-gliadin isoform and its digest (proteolyt-
ic-resistant fraction after pepsin and trypsin digestion) are fre-
quently used to study the gliadin-mediated effects on primary
cultures and cell lines.[38] The rationale behind this choice is
that the gliadin digest most closely mimics the in vivo situa-
tion. Due to gliadin’s incomplete degradation, a vast array of
mostly unknown small and large peptides comes into contact
with the gut epithelium and after transcellular and/or paracel-
lular translocation with the lamina propria, they can be recog-
nized by the mucosal immune system.
6.1. The Gut-Associated Lymphoid Tissue
The mucosal immune system has the relevant task to distin-
guish which of the many luminal antigens that it encounters
are benign to the host, for instance, food proteins and com-
mensal flora, and which of them form a danger to the host, for
instance, invading pathogens. Under normal conditions, a
milieu of immune tolerance reigns at the mucosal site, but the
mucosal immune system must possess a readiness to mount
an adequate proinflammatory immune response to danger sig-
nals to protect the host. Different cell types take part in these
elaborate dynamics.[39] Intestinal epithelial cells (Figure 4a) are
the first level of control, as they “sense” the nature of the lumi-
nal environment (Figure 4b) and send crucial information to
underlying immune cells, for example, by the production of cy-
tokines and expression of membrane receptors (Figure 4c–e).
The gut-associated lymphoid tissue from the small intestine
consists of effector sites, that is, scattered lymphocytes in the
lamina propria (Figure 4 f) and epithelium and organized tis-
sues such as Peyer’s patches and mesenteric lymph nodes (Fig-
ure 4g,h). In particular, the mesenteric lymph nodes are crucial
for the induction of tolerance and immunity. Generally, the an-
tigen is taken up by dendritic cells and is presented in the con-
text of HLA class II to CD4+ T cells.[40] Possible places at which
antigen uptake can occur are Peyer’s patches (Figure 4g) and,
if the antigen has gone through the epithelial monolayer, the
villous lamina propria (Figure 4 f). The antigen-loaded dendritic
cells within the Peyer’s patches can present to CD4+ T cells
in loco or can migrate from the Peyer’s patches via afferent
lymphatics to the mesenteric lymph nodes and present there
to CD4+ T cells. Likewise, villous lamina propria dendritic cells
can reach the mesenteric lymph node via afferent lymph ves-
sels, and there they present the antigen to CD4+ T cells (Fig-
ure 4g–i). Wherever the site of antigen uptake may be, all anti-
gen-primed lymphocytes obtain the intestinal homing mole-
cule, a4b7, and leave the mesenteric lymph node via efferent
lymph vessels and re-enter the intestinal mucosa at which they
take their particular place. For example, B cell blasts mature
into IgA-producing plasma cells and remain in the lamina
propria (Figure 4k), CD4+ T cells are distributed over the villus
lamina propria (Figure 4 j), whereas most CD8+ T cells migrate
to the epithelium. The T cells can provide help as effector cells
to B cell plasmablasts to produce IgA, and they can be anti-
gen-specific memory CD4+ and CD8+ T cells or regulatory
T cells. CD8+ T cells also can exert strong cytotoxic activity, usu-
ally to antigens that are present in the context of HLA class I
molecules.[40b]
Antigen-primed CD4+ T cells are involved in local immune
regulation and produce large amounts of interferon (IFN)-g, in-
terleukin (IL)-4, and IL-10.[41] The coexistence of these different
cytokines is a feature of normal homeostasis, and disturbances
in their secretion reflect pathogenesis of gastrointestinal disor-
ders, such as the high mucosal titers of IFN-g in the active
phase of CD.[42] The production of IL-10 is essential in the
maintenance of tolerance (Figure 4e, i, j), whereas in immunity
it is crucial in the regulation of inflammation.[41b] In addition to
the environmental factors derived from the intestinal lumen,
such as food proteins or bacterial products, genetically deter-
mined (host) factors may impact the immunological outcome.
As professional antigen-presenting cells, the dendritic cells in-
tegrate these genetic and environmental factors and shape the
T lymphocytes, to which they present the antigen, to maintain
intestinal homeostasis or to induce immunity. Other features of
intestinal tolerance are the abundant production of the cyto-
kines TGF-b and IL-10 by tissue macrophages, mesenchymal
cells, and epithelial cells and, furthermore, the production of
the enzyme cyclo-oxygenase 2 (COX-2) by epithelial cells (Fig-
ure 4c). COX-2 is an essential mediator in the synthesis of pros-
taglandin-2 (PGE2) from arachidonic acid, and it fulfills a crucial
role in immune tolerance. PGE2 increases IL-10 production, de-
creases proinflammatory mediators such as HLA class II, IL-12,
tumor necrosis factor (TNF)-a, and primes dendritic cells to
shape T cells to tolerogenic and regulatory T cells (Figure 4e, i).
Inhibition of COX-2 in a murine model results in features char-
acteristic of celiac disease possibly due to T-lymphocyte stimu-
lation in an environment deprived of COX-2-dependent arachi-
donic acid metabolites.[43]
In case pathogens are encountered, local inflammation is in-
duced by Toll-like receptor (TLR)-mediated production of in-
flammatory mediators, such as IL-1, IL-6, and IL-8 by macro-
phages, mesenchymal cells, and epithelial cells (Figure 5a).
This inflammatory environment shapes the dendritic cells
(DCs). As a result, the DCs undergo complete maturation after
having taken up the antigen in the Peyer’s patches or lamina
propria (Figure 5b) and start to produce the proinflammatory
cytokine IL-12. Under these circumstances, antigen presenta-
tion to naı¨ve CD4+ T cells leads to their differentiation into
gut-homing Th1 cells, which produce IFN-g and cause further
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inflammation (Figure 5c). Likewise, plasmablasts home to the
intestinal mucosa and mature into IgA-secreting plasma cells
(Figure 5d). These events lead to local immunity and IgA
production.
6.2. The (Patho-)Physiological and Immunogenic Properties
of the Gliadin Digest
Gliadin digest induces physiological changes and immunologi-
cal responses, many of which are observed in both health and
disease, albeit the measure of these effects of gliadin is much
higher and prolonged in disease. In this scenario, specific and
characteristic for the active phase of celiac disease are the
presence of gliadin-restricted Th1/Th17 T-cell-mediated
immune responses (Figure 5c, e),[42,44] an increase in intraepi-
thelial lymphocytes (Figure 5 f), and villus blunting (Figure 5g).
In the gut lumen, the gliadin digest first interacts with the
intestinal epithelium. It is still a matter of debate how gliadin
and its digestive fragments pass the enterocyte monolayer, but
available information suggests the involvement of both trans-
cellular (Figure 5g,h) and paracellular pathways (Figure 5 i).
Some evidence for endocytosis of gliadin and its digest is
shown by the finding that gliadin fragments induce remodula-
tion of the actin cytoskeleton, which interferes with the brush-
border membrane trafficking of vesicles.[45] Another school of
thought includes the possibility of paracellular transport over
the intestinal epithelium.[46] In this respect, it has been shown
that the gliadin digest binds to the apically expressed chemo-
kine receptor (CXCR3).[47] Gliadin’s interaction with CXCR3 indu-
ces the secretion of zonulin, a physiological modulator mole-
cule of intestinal permeability, which in turn binds, through
transactivation of the epithelial growth factor receptor (EGFR),
to protease-activated receptor 2 (PAR2).[48] These interactions
Figure 4. Intestinal homeostasis. Under normal conditions, the intestinal environment is an environment that favors tolerance to allow commensal bacteria
and dietary antigens and maintain intestinal homeostasis. Intestinal epithelial cells (a) form a tight barrier between milieu exterieur and milieu interieur. They
sense the nature of the luminal antigens and send information to underlying immune cells, for instance, by the production of tolerogenic cytokines (c–e).
Food antigens and products from the microflora (b) are taken up by dendritic cells (DCs) in the lamina propria (f) or Peyer’s patches (g). In the absence of in-
flammation, DCs then undergo partial maturation under the influence of prostaglandin 2 (PGE2) and IL-10, produced by macrophages and mesenchymal cells
(e), and transforming growth factor (TGF)-b and COX-2 produced by epithelial cells (c,d). DCs produce the anti-inflammatory cytokine, IL-10, and present the
antigens to naı¨ve CD4+ T cells in the Peyer’s patches or mesenteric lymph nodes (h), in which they differentiate into regulatory T cells under the influence of
IL-10 (i). From the mesenteric lymph node, recirculation and homing to the mucosa of T cells (j) and plasmablasts occur (k). These events lead to local IgA pro-
duction and immune tolerance.
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lead to reorganization of the cytoskeleton, which results in dis-
assembly of the tight junctions, interepithelial protein com-
plexes that regulate permeability.[44] Barone et al.[49] report an
epithelial growth factor (EGF)-like effect of gliadin, including
EGFR activation, rearrangement of the actin cytoskeleton, and
changes in cell cycle and cell proliferation (Figure 5 j). Using
normal mice and MyD88-deficient mice, Thomas et al.[50] have
shown that the effects of gliadin digest on intestinal permea-
bility and zonulin release requires MyD88 recruitment. Al-
though the involvement of MyD88 commonly indicates signal-
ing by TLRs, this study shows that the two most plausible—if
any—candidates, TLR2 and TLR4, seem not to be implicated in
this response. Although it cannot be excluded that other TLRs
might be involved in gliadin-induced intestinal permeability,
the CXCR3 chemokine receptor has been found to co-localize
with MyD88 and appears to possess a Toll/Interleukin receptor
(TIR)-like domain, which strongly suggesting its (mere) involve-
ment in gliadin-induced, MyD88-mediated signaling.[47] In cul-
tured duodenal biopsy specimens from healthy individuals and
celiac patients, Drago et al.[51] have confirmed that gliadin and
its digested fraction induce the release of zonulin and increase
intestinal permeability and, furthermore, report disease-specific
qualitative and quantitative differences. Thus, whereas the re-
lease of zonulin and an increase in permeability are small and
short-lived events under healthy conditions, both the release
of zonulin and the accompanying breach of barrier function
are massive and difficult to restore in celiac tissues. Notably,
during the active phase of celiac disease, in addition to in-
creased intestinal permeability zonulin titers are elevated[52]
and mucosal expression of CXCR3 is increased (Fig-
ure 5 i, k).[47,53]
Figure 5 further depicts inflammatory features that have
been described explicitly for CD, the gluten-induced autoim-
mune enteropathy that is characterized by aberrant Th1/Th17
T-cell-mediated immunity and auto-antibody production lead-
ing to severe intestinal damage (Figure 5e–m). See text for de-
tailed discussion of these features.
All markers return to baseline expression levels after imple-
mentation of a gluten-free diet once the disease goes into re-
mission. Gliadin’s interaction with intestinal epithelium produ-
Figure 5. Immunity in celiac disease. Whereas under normal conditions an environment of mucosal tolerance exists, there is at the same time a readiness to
mount an inflammatory immune response if needed, such as in the case of danger signals (invading pathogens). If pathogens are encountered, local inflam-
mation is induced by the production of inflammatory mediators, such as IL-1, IL-6, and IL-8 by macrophages, mesenchymal cells, and epithelial cells (a). This
inflammatory environment shapes the DCs, and as a result, they undergo complete maturation after taking up the antigen in the Peyer’s patches or lamina
propria (b) and start to produce the proinflammatory cytokine, IL-12. Naı¨ve CD4+ T cells differentiate under the influence of IL-12 into gut-homing Th1 cells,
which produce IFN-g and cause further inflammation (c). Likewise, plasmablasts home to the intestinal mucosa and mature into IgA-secreting plasma cells (d).
This event leads to local immunity and IgA production.
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ces stressful effects such as an oxidative imbalance,[38] the pro-
duction of IL-15 and IFN-g,[54] and apoptosis if the cells are ex-
posed to gliadin for 48 h.[55] Furthermore, the gliadin fragments
can induce both an upregulation of epithelial expression of
HLA-E and MICA (major histocompatibility complex class I
chain-related gene A) molecules, which are ligands for their re-
spective receptors, CD94 and NKG2D, and selective expansion
of subsets of intraepithelial CD8+ cytotoxic T lymphocytes that
express CD94 and NKG2D.[56] These pathways are thought to
be mechanisms that regulate cytotoxic T-lymphocyte activity
in injured cells, thereby minimizing potential damage to adja-
cent intact cells. Usually, cytotoxic T lymphocytes need co-stim-
ulation with T-cell receptor (TCR) signaling, but recent studies
convincingly show that IL-15 can induce changes in the
NKG2D signaling pathway that allows for a TCR-independent
conversion of CD8+ cytotoxic T lymphocytes into natural killer-
like cells. Most of these events are inhibited by neutralizing an-
tibodies to IL-15, which thus confirms the key role of this cyto-
kine as a mediator of intestinal mucosa damage.[57] Although
the gliadin digest can induce epithelial IL-15 production under
normal conditions,[56,58] IL-15 titers are much higher and intra-
epithelial lymphocyte numbers are significantly increased in
active celiac disease relative to healthy individuals, which sug-
gests a role for aberrant activation of the IL-15/NKG2D signal-
ing pathway in the massive tissue damage observed in active
celiac disease (Figure 5g).[59] To understand further the effects
of gliadin’s digest on innate immune cells, peripheral blood
mononuclear cells and primary cells and cell lines from phago-
cytic lineage have been used in stimulation assays. In peripher-
al blood mononuclear cells from healthy individuals and CD
patients, the gliadin digest induces the production of various
cytokines, including TNF-a, IL-10, and IL-8. The latter cytokine
appears to be produced in a CXCR3-mediated fashion only in
CD patients. Its cellular sources are monocytes and plasmacy-
toid dendritic cells.[60] In normal murine peritoneal macrophag-
es, gliadin stimulates the production of TNF-a, RANTES, IL-10,
and IL-8 and a significant rise in nitric oxide (NO), another me-
diator of inflammation. These effects are dependent of prior
priming of the cells with IFN-g.[61] Jel&nkov# et al.[62] report simi-
lar effects for the human monocyte cell lines, THP1 and U-937,
with gliadin-induced production of IL-8 and TNF-a through the
activation of the NFkB signaling pathway, and a synergistic
effect of IFN-g has also been shown in human cells. Thomas
et al.[50] show in a normal murine model that the gliadin digest,
in addition to MyD88-dependent release of zonulin and in-
creased intestinal permeability, also induces the production of
proinflammatory cytokines, among which are TNF-a, IL-12, IFN-
b, and CXCL10, by macrophages. As signaling through TLRs re-
cruits the adaptor molecule MyD88 and leads to NFkB activa-
tion, the study assesses a role for TLR2 and TLR4 in gliadin-in-
duced immune responses but does not find evidence for their
involvement. In contrast, Palov#-Jel&nkov# et al.[63] have found
that TLR4 is involved in gliadin-digest-induced NF-kB activation
and IL-1b production by human monocytes. As the effects are
not observed after stimulation with synthetic gliadin peptides,
the authors do not exclude that another component within
the digest, for instance, the amylase tryptase inhibitor for
which a TLR4-mediated effect was previously described by
Junker et al. ,[64] could be responsible for the observed effects.
Another effect of gliadin is its neutrophil chemoattractant
properties.[65] Upon applying gliadin digest in the intestinal
lumen of C57BL/6 Lys-eGFP mice, CD11b+Ly6G+ cells (a subset
consisting of murine macrophages and neutrophils) rapidly mi-
grate from the vessels into the lamina propria. With in vitro
chemotaxis assays, migration of isolated murine and human
neutrophils to the gliadin digest has been shown. Notably, the
gliadin digest and the classical neutrophil chemoattractant,
f-Met-Leu-Phe, both induce similar neutrophil migration. Spe-
cific inhibition of the f-Met-Leu-Phe receptor, the formyl pep-
tide receptor 1 (FPR1), not only blocks neutrophil migration to-
wards f-Met-Leu-Phe but also towards gliadin, which indicates
that gliadin also binds to FPR1.[65] The adaptive immune re-
sponse specific for celiac disease consists of a Th1-mediated
mucosal immune response of gliadin-specific CD4+ T cells with
a particular cytokine pattern (IL-10+ , IL-2low, IL-4@ , IFN-g+).[57]
Recently, reports have described the presence of Th17 cyto-
kines in active CD, in particular IL-17A,[44] which suggests the
involvement of a Th17-mediated immune response in CD (Fig-
ure 5e). Important in the regulation of the Th17-mediated
immune response are the CD4+CD25+ +FoxP3 (forkhead box
protein 3)+ regulatory T cells.[66] Although regulatory T cells are
increased in number in active CD,[67] their suppressive function
seems impaired (Figure 5 i).[68] Granzotto et al.[68b] show that
regulatory T cells from CD patients are impaired in their ability
to suppress the proliferation of CD4+CD25@ responder cells
after CD3/CD28 co-stimulation in comparison to regulatory
T cells from healthy individuals (Figure 5c). In their study,
Serena et al.[68a] demonstrate overexpression of the alternative-
ly spliced isoform of FoxP3 in CD mucosa. This splice variant
cannot properly downregulate the expression of RORgt, a tran-
scription factor that is essential in Th17 differentiation, possibly
favoring skew towards a Th17 immune response (Figure 5e).
Figure 6 provides a summary of the reported effects of the
gliadin digest in vivo.
Figure 6. Summary of reported gliadin digest effects in vivo. The figure de-
picts the effects of gliadin digest that are reproduced by specific peptide
fragments within the digest, as described in Section 7.
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7. Identification of Gliadin Peptides and Their
Pathological Role
Gliadin peptides can be classified as “toxic” or “immunogenic”
depending on their ability to induce intestinal damage in vivo
and/or in vitro or to activate T cells, respectively.[69] Specific syn-
thetic gliadin fragments recapitulate many of the abovemen-
tioned effects of the full gliadin digest. A 13-mer peptide, de-
rived from a9-gliadin (aa 31–43), has been reported to be
toxic.[70] Another fragment 33 amino acids long is recognized
as the most proteolytic-resistant and immunogenic peptide
and is named a 33-mer gliadin peptide (aa 57–89 from a2-glia-
din).[25a] More recently, Tuckova et al. have identified 12-mer
and 14-mer peptides.[61] Lammers et al. report a CD-related 17-
mer peptide (aa 270–286),[60] two intestinal-permeating 20-mer
peptides (aa 120–140, aa 160–180), and a number of 20-mer
neutrophil chemoattractant peptides.[65]
7.1. The Toxic 13-mer Gliadin Peptide (aa 31–43)
The 31–43 peptide sequence has been detected mainly in a-9
gliadin (Figure 7). It was first obtained by in vitro cyanogen
bromide cleavage, and this sequence has been tested as a syn-
thetic peptide in jejunal mucosa of untreated patients and has
been shown to induce histological damage.[71] From an immu-
nological perspective, this peptide induces several pleiotropic
effects without binding to HLA-DQ2/DQ8 and without stimu-
lating CD4+ T cells. These effects include rapid production of
inflammatory mediators, such as IL-15 and COX-2; upregula-
tion of CD25 on non-T cells (CD3-negative cells) ; and CD83 ex-
pression on resident dendritic cells in the lamina propria.[70b,71]
Furthermore, the peptide increases the intraepithelial migra-
tion of CD8+ T cells and CD94+ cells and increases enterocyte
apoptosis. The results are dependent on IL-15, as the addition
of neutralizing antibodies to IL-15 abrogates the effects (Fig-
ure 5g). To explore the in vivo effect of this peptide, Araya
et al. have applied the peptide intraluminal in the intestine of
normal mice during surgery and have studied the responses in
these mice. The results show that the peptide causes histologi-
cal changes similar to those observed on CD, such as increased
intraepithelial lymphocytes and reduced villus-crypt ratio. Fur-
thermore, the peptide induces an increase in epithelial cell
death and increases titers of inflammatory mediators, in partic-
ular of type I interferon. These effects are dependent on the re-
cruitment of MyD88, but a role for TLR4 can be ruled out. In-
terestingly, co-administration of poly I :C, the ligand for TLR3,
enhances the immune response. As TLR3 is known for its spe-
cificity to recognize viral single-stranded RNA, the authors con-
clude that the gliadin peptide p31-43 can activate the innate
immune pathways in vivo and suggest a potential interaction
may exist between dietary gluten and viral infections.[72]
One crucial intracellular pathway implicated in the pathoge-
nicity of the 13-mer peptide is EGFR activation. Upon exposure
to the 13-mer peptide, both the Caco-2 cell line and culture
biopsy specimens from CD patients show signs of actin remod-
eling and cell proliferation reminiscent of the effects induced
by EGF. Although not a ligand for EGFR, the 13-mer peptide
prolongs activation of EGFR by interfering with EGFR endocy-
tosis.[73] In another study, Barone et al show that in a search for
sequence similarity, the 13-mer peptide resembles hepatocyte
growth factor regulated tyrosine kinase substrate (Hrs), which
is a crucial regulator protein of endocytic maturation. The ob-
served accumulation of the 13-mer in the early endosomes
might then occur because the peptide would interfere with
Hrs and its proper functioning. As a consequence, the 13-mer
delays maturation of early endosomes into late endosomes,
the compartment in which degradation of peptides takes
place, and additionally, it delays EGFR degradation.[73a] The per-
petuation of EGFR activation may be of importance in the de-
velopment of epithelial blunting, as observed in active CD (Fig-
ure 5 j). Luciani et al. show the accumulation of the peptide in
LAMP-containing lysosomes. The continued presence of the
peptide in the cell causes cellular stress, as measured by an in-
crease in the levels of radical oxygen species, elevated titers,
and activation of tissue transglutaminase 2 and downregula-
tion of peroxisome proliferator activator receptor (PPAR)-g,
which activates the innate immune response.[74]
Another critical topic to evaluate is how the 31–43-mer can
travel through the gut mucosa. Vilasi et al. have shown with a
simple micellar model that this peptide can possibly interact
with membranes.[75] A recent study making use of chemical
cross-linking to stabilize the peptide on proteins expressed on
the cell surface and pull-down of the peptide–protein com-
plexes with antibodies raised against peptide 31–43 did not
find specific complexes between cellular proteins and the 13-
mer peptide. Also, in competitive binding experiments the
peptide could not displace bound peptide, which suggests
nonspecific binding. On the basis of this result, the authors hy-
pothesize that no receptor might be involved in the trafficking
of the 13-mer peptide.[76]
7.2. The Immunodominant 33-mer Gliadin Peptide
(aa 56–87)
The 33-mer peptide (see Figure 7) was obtained by Shan
et al.[25a] after the enzymatic degradation of a-2 gliadin by gas-
Figure 7. Summary of different gliadin fragments with their known patho-
logical behavior.
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tric, pancreatic, and brush border peptidases. Recently, the
quantification of the 33-mer by liquid chromatography tandem
mass spectrometry in different wheat species and cultivars has
been performed. This report shows that after proteolysis, the
33-mer remains in the range of 91 to 603 mgg@1 in wheat flour,
which justifies the importance of this fragment in the human
diet.[77] This highly proteolytic-resistant peptide harbors six epi-
topes that are in part overlapping. By an unknown mechanism,
it reaches the lamina propria, at which dendritic cells process
and present it in the context of HLA-DQ2/8 to CD4+ T lympho-
cytes.[25a] In general, proteins cross the epithelium by the trans-
cellular pathway followed by lysosomal degradation. As for the
other gliadin peptides, there is an ongoing debate on the
mechanism of epithelial translocation. Schumann et al.[78] have
studied 33-mer peptide transcytosis in Caco-2 cells and duode-
nal biopsy specimens from healthy individuals and active CD
patients and have found evidence for transcellular transport of
the 33-mer peptide to the lamina propria through an endocyt-
ic pathway involving Rab-5. Addition of IFN-g, the hallmark cy-
tokine in active celiac disease, enhances translocation of the
peptide in Caco-2 cells. Compared to duodenal tissues from
healthy individuals and CD patients in remission, tissues from
active CD patients reveal significantly higher epithelial uptake
of the peptide seemingly localized in endocytotic vesicles. The
data presented by M8nard et al.[79] suggest a transcellular path-
way for the 33-mer peptide. Their immunofluorescent images
show co-localization of the peptide with early endosome anti-
gen 1, which indicates that the peptide enters the early endo-
somes. However, no co-localization is found with lysosomal-as-
sociated protein 2, which suggests that the peptide does not
enter the late endosomes or lysosomes, the cellular compart-
ment in which peptide degradation is thought to occur. These
authors hypothesize that this is in line with their other
study,[80] in which they demonstrate that the 33-mer peptide is
transported to the lamina propria while escaping the lysoso-
mal compartment by binding to lumenal secretory immuno-
globulin A (sIgA); thus, lysosomal degradation was impaired.
The gliadin–sIgA complex is recognized by the apically ex-
pressed transferrin receptor, CD71, and is “retrotranscytosed”
to the lamina propria (Figure 5h). This mechanism would only
occur in active CD, for which, in contrast to the healthy condi-
tion in which CD71 is solely expressed at the basolateral site of
the cells, the receptor is aberrantly expressed at the apical side
of the enterocyte. Finally, Bethune et al.[81] describe two possi-
ble mechanisms for epithelial translocation of the 33-mer pep-
tide by using a T84 cell-culture model. In response to condi-
tioned medium from gliadin-treated T cell cultures from CD pa-
tients, epithelial cell permeability is increased and apically ap-
plied 33-mer peptides make use of the paracellular pathway to
translocate. This process occurs mainly in the presence of high
concentrations of IFN-g, and the addition of neutralizing anti-
bodies to IFN-g or anti-IFN-g-receptor blocking antibodies in-
hibits paracellular transport. In the absence of gliadin-condi-
tioned medium or IFN-g, transcellular transport of the 33-mer
seems to take place without the involvement of a receptor.
These authors conclude that under healthy conditions, gliadin
peptides use the transcellular pathway in a receptor-independ-
ent way though fluid-phase endocytosis, whereas under in-
flammatory conditions an IFN-g-induced increase in the intesti-
nal permeability results in increased paracellular translocation
of gliadin.
In celiac patients, a characteristic and well-known T-cell re-
sponse (adaptive immune response) is observed if the peptide
enters the gut mucosa. In the lamina propria, the 33-mer pep-
tide is a high-affinity substrate for tissue transglutaminase 2,
an enzyme that deamidates three glutamines to glutamic acid
(Figure 5m). This deamidated peptide is much more immuno-
genic and induces a stronger adaptive immune response. Ad-
ditionally, the 33-mer peptide contributes to b-cell hyperactivi-
ty observed before the onset of type 1 diabetes, at least in
murine models.[82] Some researchers have considered that glia-
din and its 33-mer fragment are handled by the host as if it
were a pathogen such as a bacterium or a virus.[83] However, al-
though there is much evidence pointing in this direction there
is no sound explanation for the observed similarities.
7.3. Other Identified Gliadin Peptides
It is important to note that frequently the exact peptide com-
position of a gliadin digest is unknown. For this reason, Tucko-
va et al. have identified different peptides from the peptic glia-
din digest by reverse-phase (RP)-HPLC–MS. These authors
report that a 14-mer fragment, VSFQQPQQQYPSSQ (named the
T peptide), and especially its shorter 12-mer form,
FQQPQQQYPSSQ (named the B peptide), elicit the highest
TNF-a, IL-10, and RANTES secretions and an increase in IFN-g-
primed nitric oxide production in mouse macrophages.[61] Like-
wise, these peptides induce IL-8 and TNF-a through activation
of the NFkB pathway in the human monocytic cell line, THP-
1.[62] Another approach described by Lammers et al. involves
the generation of a a-gliadin synthetic peptide library consist-
ing of 25 20-mer peptides each overlapping in 10 amino acids.
This library has been used to identify the fragments responsi-
ble for the observed gliadin-digest-induced effects
(Figure 7).[47] A total of 16 novel gliadin peptides have been de-
scribed to be involved in three different responses, for exam-
ple, intestinal permeating effects,[47] immunogenic effects, and
neutrophil migratory effects.[65] Using the synthetic a-gliadin
peptide library, two peptides, QQQQQQQQQQQQILQQILQQ (aa
120–140) and QVLQQSTYQLLQELCCQHLW (aa 160–180), have
been identified as the specific gliadin fragments that bind to
epithelial CXCR3 (Figure 5 i). Furthermore, unlike nonbinding
peptides, these two CXCR3-binding peptide fragments also
induce tight junction disassembly. The second finding is relat-
ed to gliadin-digest-induced immune stimulation of peripheral
blood mononuclear cell cultures and shows that the cellular re-
sponse to gliadin is differentially regulated in CD than in
health with the involvement of the CXCR3 chemokine receptor.
In this study, the cell cultures from both healthy individuals
and celiac disease patients respond to gliadin digest by pro-
ducing substantial titers of an array of proinflammatory media-
tors, including interleukin-8.[60] Solely in the wells that contain
cells from celiac patients, but not those containing cells from
healthy individuals, a preincubation step with an antibody that
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blocks CXCR3 before stimulation with the gliadin digest results
in complete inhibition of IL-8 production. With the use of the
abovementioned synthetic a-gliadin peptide library, a third
peptide, PPYCTIVPFGIFGTNYR (aa 270–286), shows a result sim-
ilar to that obtained with the gliadin digest regarding the
CXCR3-mediated production of IL-8 by cells from the phago-
cytic lineage from CD patients. Finally, this approach has
allowed the researchers to individuate another 13 peptides
that induce FPR1-mediated, moderate-to-strong neutrophil
migration.
Altogether, these findings reveal exciting information on a-
gliadin and illustrate the molecular complexity of the protein
and its interaction with the host.
8. The Supramolecular Behavior of 33-mer
Gliadin Peptide: A New Hypothesis
There is evidence that the 33-mer peptide is transported
within the body because it is detected in urine and feces.[84] It
seems that the 33-mer gliadin peptide can escape all the pro-
teolytic pathways involved in digestion; it crosses the gut epi-
thelium and reaches the lamina propria at which it induces an
immune response in susceptible individuals. Up to now, the
immunogenic effect of the 33-mer peptide in CD has only
been explained by T-cell recognition. However, there is no ex-
planation to put forward all the other exceptional properties
of this gliadin fragment.
The immunogenicity of a protein or peptide depends not
only on its primary sequence but also on the secondary and
tertiary structures. Because of this, the structural features of
the immunodominant 33-mer peptide are essential to under-
stand gluten-related pathologies. Initially, it was reported that
the 33-mer peptide adopts a PPII (polyproline II) structure.[25a, 85]
Then, a more detailed circular dichroism study, performed by
Herrera et al. , has shown that the 33-mer peptide suffers a
conformational transition depending on the concentration
under physiological conditions.[86] At low temperature (@10 8C),
at a concentration below 197 mm, the peptide is in a random
coil structure, whereas at a concentration exceeding 197 mm,
the peptide is in an equilibrium between the random coil and
a more extended structure compatible with a PPII structure.
The PPII structure is, in general, in equilibrium with other con-
formations, such as random and b structures due to the prox-
imity of the respective dihedral angle. In a temperature-de-
pendence experiment from @10 to 37 8C, it is possible to de-
termine that at a concentration of 197 mm an equilibrium be-
tween the random coil and the PPII structure exists, whereas
at a concentration of 613 mm a second conformational equilib-
rium exists between the PPII and b structures. Under these ex-
perimental conditions, the 33-mer oligomerizes in a concentra-
tion-dependent manner. Electron microscopy observations
show that the 33-mer can oligomerize to form nanospheres, fi-
brils, and fibers that coexist together at 613 mm. Molecular dy-
namics simulation and partial charge distribution calculations
have revealed that the 33-mer peptide is a nonionic amphi-
phile with the capability to form, at least, a stable dimer.[86]
Insight into the oligomerization process depending on con-
centration has been obtained by using dynamic light scatter-
ing (DLS) and atomic force microscopy (AFM). DLS experiments
reveal that at concentrations ranging from 125 to 610 mm, the
33-mer gliadin peptide forms oligomers of different sizes.
Three oligomeric populations have been identified: a popula-
tion of oligomers with a size smaller than 100 nm, a second
population of oligomers with sizes between 100 and 1000 nm,
and a third population of oligomers with sizes greater than
1000 nm.[87] These results strongly suggest that in aqueous so-
lution the 33-mer peptide behaves as a dynamic polydisperse
system with nanometer-to-micrometer-sized particles, and at
low concentrations the smaller particles associate to generate
bigger ones. However, at high concentrations, the bigger parti-
cles seemingly act as new sites for nucleation, which limits the
interaction between the small ones. AFM observations visualize
the different oligomers in a hydrated state without chemical
manipulation. Deposition of an aliquot of a 6 mm solution onto
a mica surface revels that the 33-mer peptide forms isolated
spherical nanostructures and clusters. In the range of 60 and
250 mm, spherical oligomers are associated with linear patterns
forming annular structures (Figure 8).
Some planar structures show a sheet-like morphology. At
the highest concentration of 610 mm, there are mainly fila-
ments and plaques surrounded by spherical nanostructures. At
all the concentrations tested, the 33-mer oligomers follow a
diffusion-limited assembly (DLA) mechanism. The structural
changes that take place during self-organization on a surface
have been followed by using attenuated total reflectance Four-
ier-transform infrared (ATR-FTIR) spectroscopy. Here, taking ad-
vantage of the fact that the absorption coefficient of the b
structure is higher in IR spectroscopy than in circular dichro-
ism, the nature of the b structure has been elucidated. Initially,
the same concentration-dependent conformational equilibrium
that was previously detected in solution was confirmed. The
ATR-FTIR spectrum of the 33-mer aggregates in the amide I
(representative of protein secondary structure) region reveals
two main bands. The intensity of the band at around n˜=
1630 cm@1 increases as a function of concentration relative to
intensity of the band at around n˜=1660 cm@1, which suggests
that the 33-mer peptide goes from a somewhat unordered
state to a more folded state, enriched in b structures. Interest-
ingly, if the peptide concentration increases, larger structures is
detected by microscopy techniques. Moreover, the absence of
a band at around n˜=1695 cm@1, characteristic of an antiparal-
lel b-sheet structure, strongly suggests a parallel b-sheet struc-
ture.[88] The PPII secondary structure is involved in protein–pro-
tein interactions, such as in motifs related to SH2 domains,[89]
and in proteins that form aggregates, such as the dental
enamel protein amelogenin.[90] On the other hand, the confor-
mational transition towards a parallel b structure is the hall-
mark signature of amyloid or conformational diseases. These
diseases involve not only misfolding of endogenous proteins,
as seen in Alzheimer’s disease,[91] but also exogenous proteins,
as in the case of prion diseases.[92] In conformational diseases,
oligomers and fibril structures are detected and associated
with innate and adaptive immune activation. The observed
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conformational changes and oligomerization behavior of the
33-mer gliadin peptide could be the up-to-now unknown mo-
lecular trigger that modulates immune activation in gluten-
consumption disorders. At the molecular level, the forces in-
volved in the self-assembly process of the 33-mer are correlat-
ed with the primary structure of the 33-mer. The 33-mer pep-
tide contains 65% proline and glutamine, which suggests that
hydrophobicity could be a driving force for self-assembly.
Moreover, it is known that glutamine residues can interact
through complementary hydrogen bonding, in addition to the
aforementioned hydrophobic effect.[93] Glutamine (Q) can link
b strands together into b sheets by a network of hydrogen
bonds between the amide groups of the chain and the polar
side chains.[94] The importance of the Q lateral chain in the for-
mation of protofilaments has been highlighted in different
amylogenic diseases, including Huntington’s disease.[95] Fur-
thermore, supramolecular organization of the 33-mer peptide
in monomers, oligomers (with different morphologies and
sizes), and protofilaments might explain the different mecha-
nisms of epithelial transport that have been reported for differ-
ent groups (Figure 9). Further experiments are needed to test
33-mer oligomers in the cellular context.
9. Conclusions and Perspectives
In the 1940s, the Dutch pediatrician Dr. Dicke observed a link
between celiac disease (CD) and gluten consumption, and
since then, the pathogenesis of CD has been widely studied.
However, even after all these years of efforts, crucial knowl-
edge is still lacking about the early interaction of gliadin with
the gut epithelium and, hence, the first steps in the pathogen-
esis of this autoimmune enteropathy. Even more, the effects of
gliadin in healthy individuals have not been systematically
studied. The broad spectrum of responses with the gliadin
digest and the more specific responses reported with the 20-
mer, 13-mer, and 33-mer peptides in different assays shows
that gliadin protein contains immune and toxic fragments in
its sequence. As mentioned, CD is characterized as a Th1-medi-
ated autoimmune disease with high mucosal titers of interfer-
on-g. As such, the adaptive immune response that is triggered
by gliadin has been extensively studied. However, recent data,
discussed extensively in this Review, have shed light on the in-
volvement of innate immunity in the host’s early response to
gluten. Gliadin alone and the remaining large peptides (gliadin
digest) are highly immunogenic if exposed to different cell
types. Moreover, if it is taken into account that innate immuno-
logical responses elicited by gliadin are reported at pH 7.0, the
hypothesis of colloidal assemblies of this protein as a real po-
tential trigger, instead of randomly dispersed gliadin mono-
mers, gains strength and may explain the reported immunoge-
nicity of gliadin and its tissue stress effects. Likewise, the micel-
lar aggregates formed at pH 3.0 may be responsible for the in-
ability of pepsin to cleave gliadin in smaller fragments
efficiently.
Moreover, the proteolytic resistance of the 33-mer and its
self-assembly behavior on impaired cellular clearance condi-
tions could explain the up-to-now unresolved question about
the initial stages of gluten-related disorders in connection with
Figure 8. Spontaneous oligomerization of 33-mer depends on peptide concentration. On increasing the peptide concentration, spherical-like oligomers under-
go a conformational transition towards sheet-like structures with a parallel b structure.[86, 87]
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the immunodominant 33-mer peptide. The formation of 33-
mer oligomers with different sizes and morphologies could
also explain the different mechanisms of cellular transport de-
scribed by the different research groups.
It seems that the 33-mer gliadin fragment might be not only
the immunodominant peptide in CD, but also its accumulation
and conformational transition towards the b-parallel structure
might connect a common food intolerance with conformation-
al or amyloid diseases.
Recently, oligomers of a radiolabeled mutated 3H-33-mer
were found in blood plasma and accumulated in different
organs in murine models after oral and intravenous administra-
tion.[96] These findings support the relevance of 33-mer oligo-
mers in vivo. Research efforts are directed towards understand-
ing the role of 33-mer aggregates in the context of the gut
immune response. Moreover, considering the relevance of pro-
tein aggregates in disease, modulation/inhibition of the oligo-
merization process of the 33-mer may open new perspectives
for the treatment of gluten-related diseases beyond the
gluten-free diet.
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